Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iNKT and CD8+ T Cells in Advanced Solid Tumors
NCT03093688Phase 2Recruiting
- Start
- Mar 2017
- Primary completion
- Dec 2030
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of autologous CD8+ antigen-specific T cells in non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), pancreatic cancer (PC) and 4 more. Primary endpoints: Incidence of adverse events related to the infusion of cells and Objective Response Rate. Started Mar 2017; status: recruiting.
02
Drugs
autologous CD8+ antigen-specific T cells
03
Conditions
non-small cell lung cancer (NSCLC)small cell lung cancer (SCLC)pancreatic cancer (PC)hepatocellular carcinoma (HCC)gastric cancer (GC)
Beyond the preview
Go deeper on NCT03093688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03093688.